参考文献/References:
[1] 孙钺,肖践明.冠状动脉支架的历史发展与未来展望[J].心血管病学进展, 2016,37(1): 23-27.
[2] Holmes DR Jr, Vlietstra RE, Smith HC, et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): A report from the PTCA registry of the national heart, lung, and blood institute[J]. Am J Cardiol, 1984,53(12): 77-81.
[3] 张新勇,马长生.药物洗脱支架与支架内再狭窄[J].临床心血管病杂志, 2009,25(7): 486-487.
[4] 陈纪林,黄静涵,杨跃进,等.比较不同药物洗脱支架置入后晚期血栓形成的发生率[J].中国循环杂志, 2009,24(6):406-409.
[5] 董何彦,马宗民,程增兵.新型无聚合物微盲孔载药支架的研究[J].辽宁师范大学学报, 2012,35(1): 99-103.
[6] 宋彩霞,周超,张海军.药物洗脱支架载药及药物释放动力学研究进展[J].中国医疗器械杂志, 2018,42(3):40-44.
[7] Ohlow MA,von Korn H,Gunkel O,et al.Incidence of adverse cardiac events 5 years after polymer-free sirolimus eluting stent implantation: Results from the prospective Bad Berka Yukon Choice registry[J].Catheter Cardiovasc Interv, 2014,84(7):1080-1086.
[8] Wessely R, Hausleiter J, Michaelis C, et al. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating[J]. Arterioscler Thromb Vasc Biol, 2005,25(4):748-753.
[9] King L, Byrne RA, Mehilli J, et al. Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial[J].Catheter Cardiovasc Interv, 2013,81(1):23-28.
[10] O’Brien B,Zafar H,Ibrahim A,et al.Coronary stent materials and coatings:a technology and performance update[J]. Ann Biomed Eng, 2016,44(2): 523-535.
[11] Anthony G,Ivan DS,Bernard C,et al.Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial[J].Circulation, 2004,109(4): 487-493.
[12] Romagnoli E,Leone AM,Burzotta F,et al.Outcomes of the tacrolimus drug-eluting Janus stent: a prospective two-centre registry in high-risk patients[J].J Cardiovasc Med(Hagerstown), 2008,9(6):589-594.
[13] Meng-yue Y, Hai-hua Z, Bo X, et al. A novel polymer-free dual-drug eluting stent with nanotechonology[J]. South China J Cardiol,2013,14(3):204-210.
[14] Zhang Y, Chen F, Muramatsu T, et al. Nine-month angiographic and two-year clinical follow-up of polymer-free sirolimus-eluting stent versus durable-polymer sirolimus-eluting stent for coronary artery disease: the Nano randomized trial[J]. Chin Med J (Engl), 2014,127(11): 2153-2158.
[15] 成永霞,邵芳,周庆国. Nano无载体药物支架对血清炎症因子的影响[J]. 中华临床医师杂志(电子版), 2015,9(15): 2828-2831.
[16] 陈新军,郑若龙,黄凤娇,等.无载体含药物洗脱支架治疗冠状动脉狭窄的临床疗效[J].实用医学杂志, 2018,34(12):2042-2045.
[17] 金慧,李猛.新型生物可降解单面刻槽载药靶向支架对冠状动脉内膜增生的影响[J].中国组织工程研究, 2017,21(26): 4222-4227.
[18] Li C, Guan C, Zhang R, et al. Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: Final five-year results of the patient-level pooled analysis from the TARGET Ⅰ and TARGET Ⅱ trials[J].Catheter Cardiovasc Interv, 2019,93(S1): 818-824.
[19] Lansky A, Wijns W, Xu B, et al. Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial[J]. Lancet, 2018,392(10153):1117-1126.
[20] Konigstein M, Banai S, Herz I, et al. Polymer-free drug-eluting stent in unselected patient population: a single center experience[J].Cardiovasc Revasc Med, 2014,15(6-7): 350-353.
[21] Im E, Hong MK. Drug-eluting stents to prevent stent thrombosis and restenosis[J]. Expert Rev Cardiovasc Ther, 2016,14(1): 87-104.
[22] Cassese S,De Luca G,Villari B,et al.Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study[J]. Catheter Cardiovasc Interv, 2012,80(3): 408-416.
[23] Park DW, Hong MK, Mintz GS, et al. Two-year follow-up of the quantitative angiographic and volumetric intravascular ultrasound analysis after nonpolymeric paclitaxel-eluting stent implantation: late "catch-up" phenomenon from ASPECT Study[J]. J Am Coll Cardiol, 2006,48(12): 2432-2439.
[24] Iofina E, Langenberg R, Blindt R, et al. Polymer-based paclitaxel-eluting stents are superior to nonpolymer-based paclitaxel-eluting stents in the treatment of de novo coronary lesions[J]. Am J Cardiol, 2006,98(8):1022-1027.
[25] Lansky AJ, Costa RA, Mintz GS, et al. Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial[J]. Circulation, 2004,109(16): 1948-1954.
相似文献/References:
[1]袁帅,毛玉琳,钱志敏,等.经皮冠脉介入术在高龄老年患者治疗中的研究新进展[J].心血管病学进展,2019,(6):864.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.007]
YUAN Shuai,MAO Yulin,QIAN Zhimin,et al.New Progress in Study of PCI in treatment of Elderly Patients[J].Advances in Cardiovascular Diseases,2019,(7):864.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.007]
[2]刘丹丹 王海珠 任凤波.ST段抬高型心肌梗死PCI术后血浆微囊泡浓度对再次血运重建的风险预测分析[J].心血管病学进展,2019,(7):1056.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.023]
LIU Dandan,WANG Haizhu,REN Fengbo.Predictive analysis of plasma microvesicles concentration in patients with ST-segment elevation myocardial infarction after target lesion revascularization[J].Advances in Cardiovascular Diseases,2019,(7):1056.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.023]
[3]潘甜 马康华.急性心肌梗死经皮冠脉介入术后冠状动脉无复流的预防和治疗进展[J].心血管病学进展,2019,(5):730.[doi:10.16806/j.cnki.issn.1004-3932019.05.017]
PAN Tian,MA Kanghua.Prevention and Treatment of Coronary Artery No-Reflow after Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2019,(7):730.[doi:10.16806/j.cnki.issn.1004-3932019.05.017]
[4]郑丽娜 范丽华 侯曼.可溶性ST2在STEMI患者经皮冠脉介入术后预后评估中的作用[J].心血管病学进展,2019,(5):827.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.040]
[5]尹涛 陶凌 胡涛.分支技术在冠状动脉慢性完全闭塞病变介入治疗中的应用[J].心血管病学进展,2019,(8):1107.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.009]
YIN Tao,TAO Ling,HU Tao.Application of Branching Techniques in Interventional Treatment of Coronary Chronic Total O cclusion[J].Advances in Cardiovascular Diseases,2019,(7):1107.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.009]
[6]郭云飞 柳景华.冠状动脉慢性完全闭塞合并分叉病变介入治疗[J].心血管病学进展,2020,(1):7.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.003]
GUO Yunfei,LIU Jinghua.Percutaneous Coronary Intervention for Chronic Total Occlusion with Bifurcation Lesions[J].Advances in Cardiovascular Diseases,2020,(7):7.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.003]
[7]徐奕 杨跃进.经桡动脉冠状动脉介入术后骨筋膜室综合征的防治[J].心血管病学进展,2020,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.001]
XU Yi,YANG Yuejin.Prevention and Treatment of Osteofascial Compartment Syndrome after Transradial Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2020,(7):1.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.001]
[8]马琛 陈少敏 崔鸣.冠状动脉慢性完全闭塞病变治疗研究进展[J].心血管病学进展,2020,(4):333.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.001]
MA Chen,CHEN Shaomin,CUI Ming.Treatment in Patients with Coronary Chronic Total Occlusion[J].Advances in Cardiovascular Diseases,2020,(7):333.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.001]
[9]奚云萍 臧雁翔 李为民.临床SYNTAX计分及其衍生计分在冠心病血运重建预后中的应用价值[J].心血管病学进展,2020,(5):452.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.004]
XI Yunping,ZANG Yanxiang,LI Weimin.Value of Clinical SYNTAX Score and Its Derivative Score in Prognosis of Coronary Artery Disease with Revascularization[J].Advances in Cardiovascular Diseases,2020,(7):452.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.004]
[10]孙一博 孙莉萍 董建增.血管炎的冠状动脉风险及手术治疗进展[J].心血管病学进展,2020,(8):821.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.010]
SUN YiboSUN LipingDONG Jianzeng.Coronary Risk and Progress in Surgical Therapy of Vasculitis[J].Advances in Cardiovascular Diseases,2020,(7):821.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.010]